Gå direkt till innehåll

Nyhetsarkiv

FDA APPROVES NEW INDICATION FOR PLAVIX (clopidogrel bisulfate) OFFERING NEW OPTION FOR PATIENTS

Sanofi-aventis and Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has approved the supplemental new drug application for the antiplatelet agent PLAVIX® (clopidogrel bisulfate) to reduce the rate of death from any cause and the rate of a combined endpoint of re-infarction, stroke or death in patients with acute ST-segment elevation myocardial infarction.

First half of 2006: Sales growth of 7.7% on a reported basis and 4.5% on a comparable basis1 Adjusted EPS1 growth of 32.9%, or 16.1% excluding selected items3

The consolidated income statement for the first half of 2006 is provided in the appendices. 2006 first-half consolidated net income after minority interests was €2,381 million, compared with €1,087 million for the first half of 2005, after the impact of the accounting treatment of acquisitions (primarily the acquisition of Aventis) and restructuring costs (€1,583 million after tax in 2006 and €1,8

Visa mer

Sanofi är ett av världens ledande läkemedelsföretag

Sanofi är ett globalt, innovativt läkemedelsföretag

Sanofi

Franzéngatan 6
112 51 Stockholm
Sverige